Prostate cancer Miniatlas

Prostate carcinoma is the second most common cancer in men worldwide. Certain risk factors have been identified, e.g. age, ethnic group, family history, hormonal levels and certain hormonal influences.

The clinical behaviour of prostate cancer ranges from a well-differentiated microscopic tumour, which may not have a significant clinical relevance, to an aggressive tumour that ultimately leads to metastasis, disease and death.

The frequency of diagnosis has increased due to the widespread use of prostate-specific antigen (PSA) in serum as a screening method.

Symptoms are an unusual presentation in men with prostate cancer and may be difficult to distinguish from symptoms caused by a benign prostate disease.

Diagnosis of prostate cancer is based upon biopsy with guidance of transrectal ultrasound, which should be preceded by measurement of serum PSA.

This miniatlas contains the following material:

Table of contents

Prostate anatomy and physiology

  • Anatomy of the prostate
  • Physiology of the prostate
  • Prostate histology

Prostate cancer, epidemiology and clinical manifestations

  • Prostate cancer
  • Epidemiology
  • Risk factors
  • Clinical manifestations
  • Differential diagnoses in prostate cancer
  • Pathogenesis
  • Pathological anatomy
  • Histological classification of prostate cancer

Prostate cancer, diagnosis and treatment

  • Diagnosis of prostate cancer
  • Determination of prostate-specific antigen (PSA)
  • Early detection of prostate cancer
  • Staging of prostate cancer I
  • Staging of prostate cancer II
  • Localized disease
  • Locally advanced disease
  • Disseminated disease
  • Radical prostatectomy
  • Laparoscopic surgery
  • Internal radiation therapy
  • External radiation therapy
  • Hormone therapy: antiandrogens
  • Hormone therapy: LHRH analogues

Metastatic castrate-resistant prostate cancer

  • Detection of metastases in castration-resistant prostate cancer (mCRPC)
  • Metastatic castrate-resistant prostate cancer (mCRPC)
  • Therapeutic approach to mCRPC
  • Options for managing mCRPC
  • Enzalutamide in the treatment of mCRPC
  • Other drugs sued in the treatment of mCRPC
  • Monitoring a patient with mCRPC

The Prostate cancer miniatlas is part of an extensive collection of illustrated medical atlases (Miniatlas Collection) covering generic specialties to specific diseases, created to facilitate doctor-patient communication.

If you would like to promote your product using this Miniatlas, please contact us.